Post by David H.

Managing Director at Cadarn Capital

uniQure, the 10th largest position in the RTW Biotech Opportunities portfolio (2.8% of NAV*), has announced a major breakthrough in partnership with University College London, successfully treating Huntington's disease for the first time.

Post content